We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Donor Human Milk and Neurodevelopmental Outcomes in Very Low Birthweight (VLBW) Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01232725
Recruitment Status : Completed
First Posted : November 2, 2010
Last Update Posted : August 4, 2017
Information provided by (Responsible Party):

October 29, 2010
November 2, 2010
August 4, 2017
August 2009
December 2014   (Final data collection date for primary outcome measure)
Cognitive scale score of the Bayley Scales of Infant Development, III [ Time Frame: 18 - 22 months' adjusted age ]
We will administer the BSID III to all subjects at 18-22 mo of age, adjusted for prematurity. We will compare the scores between subjects who received donor human milk to those who received preterm infant formula
Same as current
Complete list of historical versions of study NCT01232725 on ClinicalTrials.gov Archive Site
  • Late Onset sepsis [ Time Frame: 4 months ]
    We will compare rates of in-hospital confirmed late onset sepsis in VLBW infants receiving donor human milk and preterm formula
  • length of hospital stay [ Time Frame: 4 months ]
    We will compare the length of initial hospital stay between infants who receive donor human milk and those who receive preterm infant formula
Same as current
Not Provided
Not Provided
Donor Human Milk and Neurodevelopmental Outcomes in Very Low Birthweight (VLBW) Infants
Clinical Epidemiologic and Biologic Studies of Donor Human Milk and Breastfeeding
Breastfeeding is an important health-promoting behavior. Human milk is the ideal diet for all infants, optimizes intellect, and provides protection against infectious and atopic diseases in childhood as well as decreasing risks for obesity, hypertension and other chronic diseases. Infants with the highest risk of life-long disability, very low birthweight (VLBW) preterm infants, are breastfed at some of the lowest rates in the US. Maternal milk is not always available, and pasteurized donor human milk is an alternative that requires investigation. Whether donor milk conveys health and developmental advantages similar to those bestowed by maternal milk is unknown. By determining the effects of donor milk on health and developmental outcomes when compared to preterm infant formula, the investigators seek to optimize outcomes in this fragile population. The hypothesis of our donor milk research is that a donor human milk diet in non-maternal milk fed VLBW infants is associated with better neurodevelopmental outcome scores at 18-22 months adjusted age than a preterm infant formula diet.
Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Neurodevelopmental Outcomes of VLBW Infants
Dietary Supplement: Donor Human Milk
Donor Human Milk, obtained from the Mother's Milk of Iowa, a HMBANA milk bank
  • Experimental: Donor Human Milk
    VLBW infants randomized to be fed donor human milk, fortified as appropriate, for all feedings for which maternal milk is not available, including infants who receive no maternal milk
    Intervention: Dietary Supplement: Donor Human Milk
  • Experimental: Preterm Formula
    VLBW infants randomized to receive preterm infant formula for any feedings for which maternal milk is unavailable, including infants receiving no maternal milk
    Intervention: Dietary Supplement: Donor Human Milk
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
May 2016
December 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • <1501 g weight at birth

Exclusion Criteria:

  • chromosomal anomalies
  • congenital heart disease
  • congenital disorders known to impair neurodevelopment
Sexes Eligible for Study: All
up to 24 Months   (Child)
Contact information is only displayed when the study is recruiting subjects
United States
K23HD057232 ( U.S. NIH Grant/Contract )
Not Provided
Plan to Share IPD: Yes
Plan Description: Contact PI to discuss data sharing
Tarah T Colaizy, University of Iowa
Tarah T Colaizy
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Principal Investigator: Tarah T Colaizy, MD, MPH University of Iowa
University of Iowa
August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP